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Abstract:
Background & aims: Hepatitis B virus (HBV) RNA can undergo alternative splicing but the relevance of this post-transcriptional regulation remains elusive. Here, the mechanism of HBV alternative splicing regulation and its impact on liver pathogenesis were investigated.
Methods: HBV RNA-interacting proteins were identified by RNA pull-down combined to mass spectrometry analysis. HBV splicing regulation was investigated in chemically and surgically induced liver damage in whole HBV genome transgenic mice and in hepatoma cells. Viral and endogenous gene expression were quantified by RT-qPCR, western blot and ELISA. Resident liver immune cells were studied by FACS.
Results: HBV pregenomic RNA-interacting proteins were identified and 15% were directly related to the splicing machinery. Expression of these splicing factors was modulated in HBV transgenic mice under liver injuries and contributed to an increase of the HBV spliced RNA encoding for HBV splicing-generated protein (HBSP). HBSP transgenic mice exhibited an attenuated hepatic damage under chemically induced liver fibrosis. The protective effect of HBSP resulted from a decrease of inflammatory monocyte/macrophage recruitment through a downregulation of CCL2 expression produced by hepatocytes. In human hepatoma cells, ability of HBSP to control CCL2 expression was confirmed and maintained in a whole HBV context. Finally, viral spliced RNA detection related to a decrease of CCL2 expression in liver of HBV chronic carriers underscored this mechanism.
Conclusion:
Microenvironment modified by liver injury increased HBSP RNA expression through splicing factors regulation, which in turns controlled hepatocyte chemokine synthesis. This feedback mechanism suggests a novel insight in liver immunopathogenesis during HBV infection.
Introduction
Constitutive splicing is an essential step for eukaryotic gene expression, generating mature mRNAs by removing introns and allowing exons to be joined together accurately. In contrast, alternate splicing (including exon skipping, intron retention, alternate 3' or 5' splice sites) contributes to the diversity of eukaryotic proteome [1] and involves in the control of expression of regulatory proteins in the viral context [2] . The splicing process is coordinated by the spliceosome, a large ribonucleoprotein complex, on specific RNA domains in association with ubiquitous transregulatory splicing factors including serine-arginine-rich (SR) and heterogeneous nuclear ribonucleoprotein (hnRNPs) families [3] .
The ability of Hepatitis B Virus (HBV) transcripts to undergo to alternate splicing (AS) has been well described in vitro and in the liver of patients with chronic infection (CHB) [4, 5] . The 3.5 kb pregenomic RNA (pgRNA) of HBV, which encodes for capsid and polymerase proteins, and constitutes the template for viral genome replication, can be alternatively spliced [6] . The major pgRNA spliced variant, SP1RNA, has one third of the viral genome deleted ("intron 2447/489") and may account for up to 30% of total HBV pgRNA. SP1RNA can be packaged in core particles, reverse-transcribed and secreted. While pgRNA packaging leads to wild-type Dane particle secretion (wtHBV), the shorter SP1RNA constitutes a matrix for defective HBV circulating particles (dHBV), varying in proportion from 0% to more than 50% of HBV forms [7] [8] [9] [10] . The regulation of SP1RNA during the course of liver disease remains poorly understood. However, recent reports in HBV infected patients have shown that the proportion of dHBV relates to viral replication, to interferon therapy failure [11] and increases with liver disease progression towards hepatocellular carcinoma (HCC) [8, 9] .
SP1RNA allows the expression of HBV splicing-generated protein (HBSP). HBSP protein shares the N-terminal 46 amino-acids sequence of the viral polymerase fused to an 6 original viral sequence constituting its C-terminal part (65 amino-acids). HBSP has been identified in liver tissues from patients with CHB [12] , in whom it can induce an immune response [13] . The function of HBSP protein in liver pathogenesis remained uncertain, although in vitro studies had suggested an impact on cell viability, proliferation and migration [12, 14] and more recently on hacking the TNF-α signaling pathway [15] .
The previous observation that dHBV particles increase with liver disease progression prompted us to investigate whether and how regulation of HBV AS and liver pathogenesis are mechanistically linked. Because, the lack of robust animal models of liver pathogenesis induced by HBV infection, we decided to investigate the viral post-transcriptional regulation in HBV transgenic mice [16] . Here we report that alteration of spliceosome machinery in HBV expressing cells is switched on by liver injury and enables a striking reduction in liver monocyte/macrophage recruitment through HBSP expression. Our findings reveal a novel paradigm whereby AS can generate a viral product able to inhibit immune-mediated inflammation and thereby down-modulate organ damage .   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 7
Materials and Methods

Mice and liver pathogenesis models
Inbred C57BL/6J HBV-transgenic mouse lineage 1.3.32 (TgHBV) has been previously described [17] . TgHBV mice express and replicate HBV in the liver under the control of HBc promoter/enhancer-II. The two independent transgenic HBSP1 and HBSP2 mice strains carry HBSP gene (333 bp) encoding for the HBSP protein under the control of the HBx promoter/enhancer I (nt 832/1371) [15] . A rabbit β-globin intron was inserted between the HBx promoter/enhancer-I sequence and HBSP gene (genotype A). HBSP1 and HBSP2 transgenic mice were generated and expanded by back-crossing against the C57BL/6J strain (>12 back-crossings). C57BL/6J invalidated for CCR2 gene expression (CCR2KO) mice were also used [18] . All experiments were performed on 2-months old, heterozygous TgHBV, TgHBSP1, TgHBSP2 or homozygous CCR2 KO and corresponding littermate (WT) male mice.
WT and TgHBV mice were treated for 7 weeks with carbon tetrachloride intraperitoneal injections (CCl 4 , 1ml/kg in oil, Sigma) twice a week to induce chronic liver fibrosis.
Fulminant liver injury was generated by surgical bile duct ligation (BDL) using double sutures of bile duct near liver junction; WT and TgHBV mice were monitored for 2 days before sacrifice. Lipopolysaccharide intraperitoneal injections (LPS, 2.5mg/kg, Sigma) three times a week for 2 weeks were performed on WT and TgHBV mice to induce liver inflammation. TgHBSP, CCR2 KO and corresponding WT mice were treated twice a week with CCl 4 (1ml/kg in oil, Sigma) for 2 and/or 10 weeks. Acute liver injury was also performed in TgHBSP1 mice by a single intraperitoneal injection of CCl 4 (1ml/kg in oil).
Thioacetamide intraperitoneal injections (TAA, 250mg/kg in PBS, Sigma) three times a week were performed on WT and TgHBSP1 mice for 2 weeks to induce liver fibrosis. TgHBV, TgHBSP and littermate WT were sacrificed 48 to 72 hours after the last injection. Mice livers 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 9
Results
Increase in HBV alternate splicing upon liver injury
To assess whether liver injury impacts on HBV splicing regulation, TgHBV were treated with either CCl 4 (7 weeks/IP) or LPS (2 weeks/IP) to induce liver fibrosis or inflammation, respectively (FigS1 and Fig.S2 ). The amount of HBV pgRNA was reduced by a 5.3 fold and a 3.9 fold in LPS and CCl 4 treated TgHBV mice, respectively (Fig.1A) as well as HBV viral load (FigS3). In contrast, HBV AS was significantly increased (Fig.1A) .
Indeed, quantification of HBV pgRNA and SP1RNA-derived forms showed a significant increase of the SP1RNA proportion in both CCl 4 and LPS-treated TgHBV mice compared to control mice (oil-TgHBV vs CCl 4 -TgHBV: 32.5±9.6% vs 49.7±17.2%, p=0.04; PBS-TgHBV vs LPS-TgHBV: 27.6±8.7% vs 42.7±10.1%, p=0.01). Additionally, HBV AS upregulation was also observed in TgHBV mice with a BDL-induced fulminant hepatitis (control-TgHBV vs BDL-TgHBV: 30.6±4.9% vs 69.0±3.0%, p=0.001) (Fig.S4 ). These results may support an influence of liver damage on HBV post-transcriptional regulation.
Previous clinical studies suggested a correlation of HBV alternative splicing and the course of liver disease [8, 9] but the relevance of HBV pgRNA splicing to liver pathogenesis remains unknown. We therefore compared liver fibrosis or inflammation following CCl 4 or LPS treatment of TgHBV and their littermate wild-type (WT) control mice. Despite the wellknown activities of HBV proteins on signaling pathways involved in inflammatory and fibrotic processes [19] , CCl 4 -treated TgHBV and WT mice displayed a comparable low stage of liver fibrosis (F2) on histological section (Fig.1B) . This was confirmed by quantification of collagen deposition and the expression of genes involved in liver fibrosis. Similarly, liver histology, staining for CD45+ cells and quantification of inflammation-inducible genes confirmed an equivalent degree of liver injury in LPS-treated WT and TgHBV mice (Fig.1C and Fig.S5 ).
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Regarding that several viral proteins may impact on liver disease, it was difficult to define the role of HBV AS and related HBSP expression in this experimental model. However, the lack of increase in CCl 4 -induced liver injury in TgHBV mice, expressing the complete HBV genome, contrasted with the exacerbations previously observed in transgenic mice expressing a subgenomic HBV sequence that is unable to express SP1RNA [20] .
Considering the high level of SP1RNA in the liver of TgHBV mice, we therefore hypothesized that HBV AS, triggered by liver injury could limit the ensuing liver inflammation and fibrosis. To understand the role of SP1RNA during liver pathogenesis, we first investigated its regulation.
Identification of HBV alternate splicing factors.
Characterization of pgRNA transregulatory splicing proteins remained a crucial prerequisite to investigate HBV AS regulation. Thus, HepG2 nuclear proteins interacting with HBV pgRNA were explored by RNA pull-down assay. Identification and relative quantification by Orbitrap mass-spectrometry showed in six independent experiments that 389 proteins were significantly associated with viral pgRNA ( Fig.2A and Table S1 ).
Classification by gene ontology according to the biological functions allowed to distinct 5 groups representing 88% of associated-proteins (12% proteins remaining classified in group "other") (Fig.2B) . The most significant group was the "RNA processing" family, which was mainly composed of factors directly involved in RNA splicing (28/68 proteins; stained in (Table S1 ). As illustrated, the proteins belonging to the "RNA processing" group have additional biological functions, which may contribute to the liver disease progression during infectious disease. Specific interaction of 9 transregulatory splicing factors, hnRNPAB, SF1, La, PSF and SRSF1,4,5,6,7 were confirmed in the pgRNA pull-down extract and not in controls (using antisense HBV pgRNA and empty beads) by western blot (Fig.2D) . The splicing factors SRSF2 and hnRNPH, absent or not significantly linked to pgRNA, were used as controls.
Splicing proteins are implicated in the regulation of HBV alternate splicing
The modulation of expression of HBV pgRNA interacting transregulatory splicing proteins (conserved inter-species) was investigated in liver extracts of TgHBV mice.
Chemical induction of fibrosis led to an overexpression of PSF and SF1 proteins, whilst LPSinduced liver inflammation increased the expression of SRSF1 and La proteins (Fig.3A) .
Despite the differential signature of splicing factors expression in both liver disease models, a comparable increase of SP1RNA proportion was observed. It was considered that AS regulation in eukaryotic cells has largely been driven by the alteration of cis-regulatory elements. These data provide additional evidence suggesting AS regulation and transregulatory proteins expression according to liver damage [21] .
Conservation of splicing factors in mammals led us to investigate their involvement on HBV AS in vitro. Once different human hepatoma cells were tested, impact of PSF, SRSF1 and La expression in viral AS regulation was investigated (Fig.3 B-D) . In Huh7 expressing HBV cells, La and PSF proteins increased SP1RNA proportion, whereas SRSF1 led to a decrease of viral splicing efficiency (Fig.3E ). This paradoxical decrease may be attributable to the fact that SRSF1 expression also considerably reduced HBV transcription, core and HBeAg expression (Fig.3D) , suggesting an impact on HBV RNA synthesis or metabolism. Taken together, these data emphasized for a possible influence of the microenvironment altered by liver injury on the expression of the HBV-regulatory splicing factors we had defined, driving regulation of the SP1RNA and consequently HBSP expression. 3 The impact of the HBV alternative splicing product HBSP on liver pathology was investigated in two transgenic mouse strains TgHBSP1&2 expressing the HBSP gene under the control of the weak hepato-specific HBx promoter (Fig.S6) CXCL10 and CX3CL1 transcripts were quantified and only CXCL10 and CCL2 were significantly reduced in the liver of TgHBSP1 compared to WT treated mice (Fig.5F ). 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 were not yet activated (Fig.S9 ). Taken together, these results did not support a direct impact of HBSP expression on CCl 4 hepatocyte toxicity as an explanation for the reduced susceptibility of TgHBSP1 mice to liver damage in the chronic exposure model.
Instead we hypothesised that HBSP expression directly down-regulated hepatocyte chemokines content and thus monocyte/macrophage recruitment, accounting for the relative resistance to liver fibrosis in TgHBSP1 treated mice. Therefore, monocyte/macrophage recruitment was investigated by flow-cytometry in the acute CCl 4 hepatitis model. As previously observed during chronic exposure, the influx of intrahepatic leucocytes and monocytes/macrophages was significantly reduced in HBSP-expressing compared to WTmice with acute liver injury (Fig.6C) . The monocytes/macrophages decreased in TgHBSP1   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 6D) and to a down-regulation of CCL2 protein in the liver (Fig.6E ). Reduced infiltration of monocytes/macrophages, known to be a major source of TNF-α[23], might also account for the decrease of TNF-α expression observed. The hepatic cells types producing CCL2 in the acute hepatitis model were further explored by immunofluorescence. CCL2 staining revealed a high signal around blood vessels and unexpectedly hepatocytes (counterstained by cytokeratin 18) were also clearly positive for CCL2 (Fig.6F ).
These data suggested that HBSP expression impacted on liver monocyte/macrophage recruitment through a down-regulation of hepatocyte CCL2 expression upon acute liver injury.
HBSP modulates CCL2 expression in hepatocytes
Our results suggested that CCL2 production by hepatocytes contributes to the recruitment of monocytes/macrophages and consequently to liver damage. Next, we 24.9±3.7 vs 33.7±2.3 ng/ml; p=0.008). In order to further explore CCL2 modulation by HBSP in a whole HBV genome context, a siRNA targeting the SP1RNA encoding HBSP was designed. In HBV-transfected HepaRG, siSP1RNA efficiently knocked down SP1RNA (6- fold decrease compared to scramble siRNA) without cross-reactivity on pgRNA expression ( Fig.7C middle panel) . Upon TNF-α stimulation, CCL2 secretion was significantly higher in HepaRG cells in which SP1RNA had been knocked down than in those transfected with a scramble siRNA (Fig.7D , lanes 10 vs 9: 46.3±4.0 vs 31.1±1.6 ng/ml, p=0.008).
To assess whether the reduction of CCL2 expression, through NF-B, in HBSP expressing cells may account for the weaker liver fibrogenesis observed in TgHBSP, CCR2 invalidated (CCR2KO) (n=5) and control (n=5) mice were treated with CCl 4 . After 2 weeks of treatment, picro-sirius staining and western blot analysis of α-SMA expression revealed less marked liver fibrosis in CCR2KO mice, highlighting the main influence of this chemokine on fibrogenesis (Fig.7E ). (Fig.8A) . For 3/6 patients from each group, liver sample size allowed the additional study of the expression of transregulatory splicing proteins. Despite exhibiting a similar stage of liver disease, SP1RNA positive compared to negative liver samples displayed a higher expression of hnRNPAB together with La and SRSF1 splicing factors (Fig.8B ), which were also up-regulated in LPS treated HBV transgenic mice. In SP1RNA negative liver samples, La protein expression was mainly observed by immunohistochemistry in nucleus while it was increased and gathered in both nuclear and cytoplasmic compartments in SP1RNA positive liver samples (Fig.8C) , highlighting the shuttling of La protein [31] .
CCL2 expression relies on SP1RNA in liver of HBV chronic infected patients
Regarding CCL2 expression on patient liver sections, a differential staining was noticed with an increase in SP1RNA negative hepatocytes (Fig.7D) . The level of intrahepatic CCL2
transcripts was further quantified and SP1RNA positive liver samples displayed a 14 fold lower CCL2 expression compared to SP1RNA negative tissues ( Fig.8D ; 0.13±0.04 vs 1.87±0.80, p=0.01, respectively).
In conclusion, enhancement of transregulatory splicing proteins expression and HBV pgRNA splicing in the liver of patients with CHB was associated with a reduction in CCL2 expression, as previously observed in transgenic mice and in vitro. Our findings support the critical role of infected hepatocyte through chemokine production in liver disease and suggest a novel feedback loop regulation displayed by HBV to counteract liver pathogenesis. 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 18
Discussion
Alternate splicing regulation of HBV transcripts was first described more than 20 years ago but its role in HBV disease has remained poorly defined [4, 5] . The proportion of dHBV has been shown to fluctuate considerably in chronic carriers and to be increased with the severity of liver pathogenesis [8, 9] . However the regulation of HBV AS and its impact on liver immunopathogenesis had not been investigated. 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 . Damaged hepatocytes have previously been suggested to be able to produce CCL2 [35, 36] but were considered a minor source compared to activated HSCs and immune cells [35, 37] . Our data highlight the significant contribution of CCL2 produced by hepatocytes in liver damage, since CCL2 downregulation in TgHBSP mice had a direct 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 Strengthened by previous clinical data reporting an increase of HBV defective circulating particles related to SP1RNA with liver disease severity [8] [9] [10] , our present study suggests a new feedback loop involving HBV AS to counteract liver injury. As proposed in Figure 8E , the hepatic microenvironment altered by liver damage may contribute to enhance splicing factors involved in HBV SP1RNA production, and thus HBSP expression.
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